Skip to content
Our Latest News, Case Studies, Webinars & More
Melbourne Seminar: Integrating Human Rights into Third-Party Risk Management: From Onboarding to Continuous Monitoring
Artificial intelligence is increasingly used in third-party risk management to help organizations manage scale, data volume, and ongoing monitoring requirements. [...]
Insights with Ethixbase360: Episode 1 – How Recipharm Approaches Third-Party Risk Management
Insights with Ethixbase360 is a video series featuring short conversations with compliance and risk leaders from across industries.[...]
Top 5 Takeaways from Our UK Anti-Bribery & Corporate Crime Webinar
In our recent webinar on the evolving UK anti-bribery and corporate crime landscape, we explored a reality that many compliance leaders are currently grappling with: SFO enforcement may [...]
Who Owns Third-Party Cyber Risk? Turning Shared Responsibility into Action in APAC
Third-party cyber risk is no longer a niche technical issue, it has become a concerning business problem with real operational and financial consequences. As supply chains grow more complex and cyber threats become more sophisticated, many organisations are asking a critical question [...]
Who Owns Third-Party Cyber Risk? Turning Shared Responsibility into Action in EMEA
Third-party cyber risk is no longer a niche technical issue, it has become a concerning business problem with real operational and financial consequences. As supply chains grow more complex and cyber threats become more sophisticated, many organisations are asking a critical question [...]
What Should Businesses Consider When Re-Entering a High Risk Jurisdiction?
Following the early January 2026 capture of Venezuelan President Nicolás Maduro, the US and Venezuelan governments have been taking steps to encourage new investment.[...]
UBO Due Diligence eBook 2026
When Ownership Transparency Becomes a Strategic Control Ultimate beneficial ownership (UBO) has moved from a background compliance consideration to a […]
2026 Outlook: Navigating Third-Party Risk in the Pharmaceutical and Life Sciences Sector
2026 Outlook: Navigating Third-Party Risk in the Pharmaceutical and Life Sciences Sector Since the release of our 2025 Outlook, the […]